Portola Pharmaceuticals, Inc. Discovering and developing novel therapeutics.
Descripción de la empresa:
portola pharmaceuticals is a biopharmaceutical company developing innovative drugs for the treatment of cardiovascular and inflammatory diseases portolaõs two most advanced programs are in phase ii clinical trials: 1) betrixaban, an oral, once-daily factor xa inhibitor being developed for stroke prevention in patients with atrial fibrillation (spaf) and for prevention of venous thromboembolism (vte) in various patient populations, and 2) elinogrel, a direct-acting, reversible oral and i.v. adp receptor antagonist initially being developed for patients with acute coronary syndrome (acs).
Palabras clave para buscar:
biopharmaceutical company, innovative drugs, treatment of cardiovascular diseases, inflammatory diseases, betrixaban, factor xa inhibitor, stroke prevention, atrial fibrillation, prevention of venous thromboembolism, elinogrel, oral and i.v. adp receptor antagonist, acute coronary syndrome, antithrombotic, thrombosis, inflammatory diseases
Dirección de la empresa :
4941 Page Ave,MICHIGAN CENTER,MI,USA
Código postal: Código Postal :
49254-1156
Número de teléfono :
5177640973 (+1-517-764-0973)
Número de fax:
5177645554 (+1-517-764-5554)
Sitio Web:
www. portola. com
E-mail :
EE.UU. Código SIC ( Clasificación Industrial Estándar Código ) :
copiar y pegar este mapa de Google a su sitio web o blog!
Pulse el botón de copiar y pegar en tu blog o sitio web.
(Por favor, cambie a 'HTML' al modo de desplazamiento en su blog. Examples: WordPress Example, Blogger Example)